Legal & General Group
NAMS icon

Legal & General Group’s NewAmsterdam Pharma NAMS Stock Holding History

Legal & General Group’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33M Buy
39,343
+5,867
+18% +$193K ﹤0.01% 2103
2026
Q1 		$1.07M Sell
33,476
-7,475
-18% -$243K ﹤0.01% 2116
2025
Q4 		$1.44M Sell
40,951
-4,787
-10% -$174K ﹤0.01% 2102
2025
Q3 		$1.3M Buy
45,738
+1,503
+3% +$36K ﹤0.01% 2164
2025
Q2 		$801K Buy
44,235
+11,106
+34% +$203K ﹤0.01% 2298
2025
Q1 		$678K Buy
33,129
+10,183
+44% +$226K ﹤0.01% 2307
2024
Q4 		$590K Buy
22,946
+7,110
+45% +$151K ﹤0.01% 2402
2024
Q3 		$263K Hold
15,836
– – ﹤0.01% 2631
2024
Q2 		$304K Buy
+15,836
New +$318K ﹤0.01% 2598

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Legal & General Group's NAMS Position: Q2 2026 in Review

Legal & General Group increased its NewAmsterdam Pharma (NAMS) stake by 18% in Q2 2026, buying an estimated $193K and bringing the position to 39,343 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2103.

Legal & General Group first reported a position in NAMS in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.44M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Legal & General Group held 39,343 shares of NewAmsterdam Pharma worth $1.33M as of Q2 2026.
  • Legal & General Group bought 5,867 NewAmsterdam Pharma shares in Q2 2026, an estimated $193K.
  • NewAmsterdam Pharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2103 holding.
  • Legal & General Group first reported a position in NewAmsterdam Pharma in Q2 2024 and has held it in 9 quarters since.
  • Legal & General Group's NewAmsterdam Pharma position peaked at $1.44M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.